Launched as an interactive dashboard, ERVISS offers weekly integrated data on influenza, RSV and SARS-CoV-2 across the EU/EEA and the WHO European Region.

Each year, RSV causes an estimated 3.6 million RSV-associated hospitalisations and approximately 100.000 RSV-attributable deaths in children under 5 years of age worldwide .

Seasonal influenza activity is low. Nationally, during Week 23, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 1.7%.

FluCov project: combining data from around the world to better understand the co-circulation of influenza and COVID-19

Estimates of current mid-season flu vaccine effectiveness (VE) in Europe and China range from 32% to 58% overall, with greater protection against influenza B than A, according to three studies published in Eurosurveillance.

This could facilitate pooled analyses linking viral genetic sequencing data to clinical severity, bringing insights to inform influenza surveillance and the vaccine strain selection process.

WHO announced them at the meeting on the composition of Influenza Virus Vaccines. These gatherings are held twice a year, bringing together an advisory group of experts from WHO Collaborating Centres and WHO Essential Regulatory Laboratories.

A new joint action focusing on tackling chronic respiratory diseases was recently launched. Backed by the EU4Health programme, the 3-year initiative aims to improve lung health across Europe through innovative digital health technologies.